What the headlines get wrong about ketamine — and why that matters for you.
Patient Education · Ketamine in the News
Last updated May 2026
On this page
When a celebrity dies and a controlled substance is named in the autopsy, the public conversation collapses into one question: Is the drug safe? It is the wrong question — or at least, a question too vague to answer. Aspirin is safe. Aspirin can also kill you. The right question is always about who is giving it, how, in what dose, with what supervision, and to whom. The Matthew Perry case is, in nearly every detail, a story about what happens when none of those guardrails exist. It is not a story about ketamine medicine.
Patients ask me about Perry almost every week — most often during their first telehealth consultation with our practice. They have read the headlines. They have seen Friends. They are scared. And they deserve a careful answer rather than a marketing one. So here is the careful answer.
The Matthew Perry case, in facts
Part One
The official cause of Matthew Perry’s death was the acute effects of ketamine, with drowning, coronary artery disease, and buprenorphine listed as contributing factors. From there, the relevant details — many of them buried beneath the celebrity coverage — change the story entirely.
The autopsy and investigation, in numbers
The five people now convicted
By May 2026, every defendant in the federal case has pleaded guilty and been sentenced. Worth noting: not one was a clinic operating within standard medical protocols. The case has been about diversion, trafficking, and the abandonment of clinical judgment.
United States v. Plasencia, et al.
Central District of California · 2024–2026
Kenneth Iwamasa
Personal assistant · No medical training
Administered the fatal injection. 41 months federal prison
Dr. Salvador Plasencia
Physician · Supplied ketamine off-the-books
Admitted his conduct fell below the standard of medical care; texts showed him mocking Perry. 30 months federal prison
Dr. Mark Chavez
Physician · Diverted ketamine for resale
Pleaded guilty to conspiracy to distribute. 8 months home confinement
Erik Fleming
Acquaintance · Intermediary to street dealer
Sourced ketamine from an illegal supplier. 24 months federal prison
Jasveen Sangha
Street dealer · “The Ketamine Queen”
Sold the lot of ketamine that produced the fatal dose. 15 years federal prison
The ketamine that killed Matthew Perry did not come from a clinic. It came from a doctor selling outside the standard of care, a street dealer, and a personal assistant injecting him six to eight times a day in a private home. That is a drug trafficking story. It is not a medical ketamine story.
— David Mahjoubi, MD
Why the legitimate treatment didn’t kill him — and why the rest did
This is the single most important point in the case, and the one most often missed: Perry’s licensed ketamine infusion therapy had been completed nearly two weeks before he died. Because ketamine clears the body quickly, that medicine could not have been present at the level found in his blood. The Los Angeles medical examiner explicitly stated this. The lethal level — roughly twenty times what we use clinically for depression — came from a separate, illicit supply, administered by a person with no training, on a schedule no physician would ever order, in combination with other sedatives, in a heated tub, alone.
One detail deserves more weight than it usually gets in the news coverage: Perry was being injected. Intramuscular injection produces a rapid, near-complete absorption of ketamine — blood levels spike within minutes and can be driven higher with each additional shot. The same daily quantity of ketamine taken as a sublingual troche or nasal spray simply cannot produce anesthetic-range concentrations, because absorption by those routes is gradual and far less complete. This is not a small distinction. It is one of the structural reasons modern telehealth ketamine medicine, including the way we prescribe it at NutraBrain, uses those routes exclusively and never injection.
Almost every element of safe practice was inverted. That is what made it fatal — not ketamine itself.
Considering ketamine for depression, anxiety, PTSD, or chronic pain? Every consultation is conducted personally by Dr. Mahjoubi.
What modern telehealth ketamine actually looks like
Part Two
If the Perry case is the worst-case template for misuse, the table below is its mirror image — the way ketamine is prescribed and used in a properly run telehealth program. The contrasts are not subtle, and the very first one is the one that matters most: route of administration.
| Category | What happened to Perry | NutraBrain Telehealth Care |
|---|---|---|
| Route | Repeated intramuscular injection — a route that absorbs almost completely and pushes blood levels up within minutes. Each additional shot stacks the peak. | Sublingual troche or intranasal spray only. Absorption is partial and gradual; anesthetic-range blood levels are functionally unreachable at prescribed doses. Never injection. |
| Dose | Six to eight unmeasured injections per day, escalating until blood levels reached the general-anesthesia range. | A defined, sub-anesthetic dose dispensed by a licensed compounding pharmacy. Quantities are limited and refills require physician review — escalation isn't possible. |
| Who was involved | A personal assistant with no medical license, no training, and no monitoring of any kind. | A board-certified physician evaluates the patient by telehealth, writes the prescription, provides written safety instructions, and reviews progress at scheduled follow-ups. |
| Patient screening | None. The supplying physician admitted in his plea that he ignored the standard of care. | A full medical and psychiatric intake, medication reconciliation, and contraindication review before any prescription is written. |
| Drug interactions | Co-use of buprenorphine and benzodiazepines — both respiratory depressants — with no clinical oversight. | Every concurrent medication reviewed in advance. Known dangerous combinations are excluded outright. |
| Setting of use | A private residence, with the actor alone in a heated jacuzzi at the time of death. | The patient's home, on a written safety protocol — never combined with alcohol, sedatives, driving, or unsupervised water exposure. |
| Source of the medication | Off-the-books vials, lozenges, and powders from a street dealer — diverted outside of any pharmacy. | A licensed compounding pharmacy, filled against a physician's prescription, with a documented chain of custody. |
Common myths about ketamine, addressed briefly
Part Three
Beyond the Perry case, ketamine carries a longer history of misconceptions worth answering directly.
No. 01 “Ketamine is just a horse tranquilizer.”
The claim
A line that travels well in headlines but says little about the medicine itself.
The reality
Ketamine was developed in 1962 for human use and has been on the World Health Organization’s List of Essential Medicines for decades. It is used in every emergency department in the country, in pediatric procedures, and in field medicine because of its remarkable safety profile relative to other anesthetics. It is also used in veterinary settings — for the same reason. The same is true of acetaminophen and many antibiotics. The veterinary use is incidental, not definitional.
No. 02 “Ketamine is addictive.”
The claim
Often repeated, particularly in the wake of high-profile recreational misuse.
The reality
Ketamine has abuse potential when used recreationally — which is why it is a Schedule III controlled substance and why supervised dosing exists. In a clinical program, sessions are spaced, dosing is fixed, and the patient does not control the supply. There is no evidence that supervised, intermittent therapeutic ketamine produces physical dependence the way opioids or benzodiazepines do. The risk profile in a clinic and the risk profile of daily unsupervised self-injection are not the same risk profile.
No. 03 “It will damage my bladder or my brain.”
The claim
A real concern, drawn almost entirely from chronic recreational users.
The reality
Ulcerative cystitis from ketamine has been documented — almost exclusively in people using grams of street ketamine, often daily, often for years. Therapeutic ketamine sessions deliver a tiny fraction of that exposure, intermittently. The same is true for the cognitive concerns; the data showing harm comes overwhelmingly from heavy chronic recreational use, not from supervised clinical dosing. We monitor for any concerning symptoms as part of standard follow-up.
No. 04 “It’s a placebo, or it only works for treatment-resistant depression.”
The claim
Two opposing versions of the same dismissal.
The reality
Ketamine has the strongest rapid-acting antidepressant evidence base of any agent in modern psychiatry. The FDA approved esketamine (Spravato) for treatment-resistant depression specifically because that population had been studied first — not because the medicine only works there. Real-world clinical use spans depression, anxiety, PTSD, and chronic pain, with substantial published outcome data.
No. 05 “All ketamine providers are essentially the same.”
The claim
An assumption that the Perry case alone should dispel.
The reality
They are not. A board-certified anesthesiologist with a defined intake, screening, monitoring, and follow-up protocol is not interchangeable with a doctor handing off vials for an assistant to use. Ask about the prescribing physician’s background. Ask how dosing is decided. Ask what happens between sessions. Ask who you call if something feels wrong. These are not pedantic questions — they are exactly the questions whose absence ended Matthew Perry’s life.
If you’re considering ketamine therapy, start with a real conversation.
Speak with a physician
Every NutraBrain consultation is conducted by a licensed physician, by telehealth, from wherever you are. We’ll tell you honestly whether ketamine is — or isn’t — the right path for your situation.
Editorial note
This page is for general educational purposes and does not constitute individual medical advice. Sources include the autopsy report released by the Los Angeles County Department of the Medical Examiner, Department of Justice press releases, and federal court filings in the Central District of California. Sentencing details current as of the May 2026 conclusion of U.S. v. Plasencia, et al. This page is updated as new developments emerge.
